Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics buys JAK1 inhibitor ACR-525 and PKCθ program from Aqilion

Neutral Impact 3 of 5 m&a

Acrivon Therapeutics said it acquired Aqilion AB's oral JAK1 inhibitor ACR-525 (formerly AQ280) and a PKCθ inhibitor preclinical program in an asset purchase, paying an undisclosed cash amount. The company says it has no obligation to make milestone or royalty payments, and a separate agreement ends prior royalty and milestone obligations on ACR-525 owed to LEO Pharma. The filing gives no financial results or deal value, so its effect on shareholders is not quantified.

Key points

  • Acrivon paid undisclosed cash consideration with no future milestone or royalty payments owed to Aqilion
  • Acrivon, Aqilion and LEO Pharma terminated prior royalty and milestone obligations on ACR-525
  • Eosinophilic esophagitis is the first potential indication for ACR-525, which is described as Phase 2-ready
  • Acrivon will host a KOL webcast on November 10, 2026, at 4:00 p.m. ET

The filing

CompanyAcrivon Therapeutics, Inc. (ACRV)
Form8-K, current report
Filed with the SECNov 6, 2026, 8:00 AM ET
Accession number0001193125-26-450779

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.